As of November 6, 2026, Calidi Biotherapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 2, 2026 to June 23, 2026, naming 1 appointment. The latest filing names D. Sanders, appointed (Form 8-K, June 23, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Calidi Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Calidi Biotherapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-02 to 2026-06-23. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Calidi Biotherapeutics, Inc. files it.
Also on the record for Calidi Biotherapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| March 31, 2026 | Stake report, Schedule 13D, by Gavrilov Ognian Anguelov | 0.3% of the class | 5%+ stakes | Source |
| March 9, 2026 | Stake report, Schedule 13D, by Gavrilov Ognian Anguelov | 9.8% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Lincoln Alternative Strategies LLC | — | 5%+ stakes | Source |
| February 4, 2026 | Stake report, Schedule 13G, by Gavrilov Ognian Anguelov | 7.8% of the class | 5%+ stakes | Source |
| October 31, 2025 | Acquired Materials in Schedule 1 | $6M | Acquisition | Source |
| August 27, 2025 | Stake report, Schedule 13G, by Lincoln Alternative Strategies LLC | 14.46% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Calidi Biotherapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Calidi Biotherapeutics, Inc. and the records around it.
Calidi Biotherapeutics, Inc. elsewhere on the record
- Acquisition Oct 2025
- Who owns it
Companies that share a holder
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Calidi Biotherapeutics, Inc.
Get an email when Calidi Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Calidi Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Calidi Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Calidi Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-23 | In | 8-K, 2026-06-23 | |||
| 2026-04-02 | Reported | not named in the filing | 8-K, 2026-04-02 |
New leaders reset buying decisions — get the Full Report on Calidi Biotherapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Calidi Biotherapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Calidi Biotherapeutics, Inc.Every change, in the filing's words
Appointed: D. Sanders
In addition, the Board appointed Dr. Sanders to serve as a member of the Audit Committee of the Board.
- On June 17, 2026, the Board of Directors (the "Board") of Calidi Biotherapeutics, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee appointed Dr. Corazon (Corsee) Sanders to serve as a Class III director of the Company, with a term expiring at the Company's 2029 annual meeting of stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation, retirement, disqualification, or removal.
- Corazon (Corsee) D. Sanders, Ph.D., age 69, is a biotechnology executive and board director with more than 30 years of global leadership experience in drug development.
- She has contributed to the clinical development and regulatory approval of multiple approved therapies.
- Dr. Sanders currently serves as a Board Director at Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), where she is also an Audit Committee member; Legend Biotech Inc. (NASDAQ: LEGN), where she serves on the Audit, Compensation, and Nominating & Governance Committees; and AltruBio Inc. (private), where she is a Board Director and Audit Committee member.
Reported
On April 1, 2026, the Board on the recommendation of the Nominating and Corporate Governance Committee appointed Scott Leftwich, a Class III director, to the Audit Committee of the Board effective immediately.
- On March 29, 2026, Mr. Allan J. Camaisa, a member of the Board of Directors (the "Board") of Calidi Biotherapeutics, Inc. (the "Company"), informed the Nominating and Corporate Governance Committee of the Board that, he intends to allow the term of his Director position on the Board to expire, which expiration date is scheduled to be the date of the Company's 2026 annual stockholder meeting.
- Mr. Camaisa's decision to allow his Director term to expire did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- In connection with Mr. Camaisa's decision, effective on the date of the Company's 2026 annual stockholder meeting, the Board reduced the size of the Board from six (6) to five (5) directors.
Tools for this story
Each opens in a new tab, filled in for Calidi Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.